Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine.

Animals Drug Resistance, Neoplasm Humans Immune Tolerance Immunotherapy Indoleamine-Pyrrole 2,3,-Dioxygenase / genetics Kynurenine / immunology Macrophages / immunology Mice Neoplasms / immunology Programmed Cell Death 1 Receptor / antagonists & inhibitors Receptors, Aryl Hydrocarbon / antagonists & inhibitors Signal Transduction T-Lymphocytes, Regulatory / immunology Tryptophan Oxygenase / genetics Tumor Cells, Cultured Tumor Microenvironment

Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
11 08 2020
Historique:
received: 01 08 2019
accepted: 14 07 2020
entrez: 13 8 2020
pubmed: 13 8 2020
medline: 12 9 2020
Statut: epublish

Résumé

Tryptophan catabolism by the enzymes indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2 (IDO/TDO) promotes immunosuppression across different cancer types. The tryptophan metabolite L-Kynurenine (Kyn) interacts with the ligand-activated transcription factor aryl hydrocarbon receptor (AHR) to drive the generation of Tregs and tolerogenic myeloid cells and PD-1 up-regulation in CD8

Identifiants

DOI: 10.1038/s41467-020-17750-z PMID: 32782249 PMC: PMC7419300
pubmed: 32782249
doi: 10.1038/s41467-020-17750-z
pii: 10.1038/s41467-020-17750-z
pmc: PMC7419300
doi:

Substances chimiques

Indoleamine-Pyrrole 2,3,-Dioxygenase 0
PDCD1 protein, human 0
Programmed Cell Death 1 Receptor 0
Receptors, Aryl Hydrocarbon 0
Kynurenine 343-65-7
Tryptophan Oxygenase EC 1.13.11.11

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4011

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA056821
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA215136
Pays : United States

Références

Mellor, A. L. & Munn, D. H. Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat. Rev. Immunol.8, 74–80 (2008).
doi: 10.1038/nri2233
Holmgaard, R. B. et al. Tumor-expressed IDO recruits and activates MDSCs in a Treg-dependent manner. Cell Rep.13, 412–424 (2015).
doi: 10.1016/j.celrep.2015.08.077
Munn, D. H. et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity https://doi.org/10.1016/j.immuni.2005.03.013 (2005).
Opitz, C. A. et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature478, 197–203 (2011).
doi: 10.1038/nature10491
Holmgaard, R. B., Zamarin, D., Munn, D. H., Wolchok, J. D. & Allison, J. P. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J. Exp. Med.210, 1389–1402 (2013).
doi: 10.1084/jem.20130066
Wirth, L. J. et al. IDO1 as a mechanism of adaptive immune resistance to anti-PD1 monotherapy in HNSCC. J. Clin. Oncol. https://doi.org/10.1200/jco.2017.35.15_suppl.6053 (2018).
Long, G. V. et al. Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study. J. Clin. Oncol.36, 108 (2018).
doi: 10.1200/JCO.2018.36.15_suppl.108
Kimura, A. et al. Aryl hydrocarbon receptor in combination with Stat1 regulates LPS-induced inflammatory responses. J. Exp. Med.206, 2027–2035 (2009).
doi: 10.1084/jem.20090560
Wang, C., Ye, Z., Kijlstra, A., Zhou, Y. & Yang, P. Activation of the aryl hydrocarbon receptor affects activation and function of human monocyte-derived dendritic cells. Clin. Exp. Immunol.177, 521–530 (2014).
doi: 10.1111/cei.12352
Liu, Y. et al. Tumor-repopulating cells induce PD-1 Expression in CD8+ T cells by transferring Kynurenine and AhR activation. Cancer Cell. https://doi.org/10.1016/j.ccell.2018.02.005 (2018).
Puccetti, P. et al. Accumulation of an endogenous tryptophan-derived metabolite in colorectal and breast cancers. PLoS ONE. https://doi.org/10.1371/journal.pone.0122046 (2015).
Ferns, D. M. et al. Indoleamine-2,3-dioxygenase (IDO) metabolic activity is detrimental for cervical cancer patient survival. Oncoimmunology. https://doi.org/10.4161/2162402X.2014.981457 (2015).
Botticelli, A. et al. Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC? J. Transl. Med. https://doi.org/10.1186/s12967-018-1595-3 (2018).
Triplett, T. A. et al. Reversal of indoleamine 2,3-dioxygenase–Mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme. Nat. Biotechnol. https://doi.org/10.1038/nbt.4180 (2018).
Riaz, N. et al. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell. https://doi.org/10.1016/j.cell.2017.09.028 (2017).
Thorsson, V. et al. The immune landscape of cancer. Immunity. https://doi.org/10.1016/j.immuni.2018.03.023 (2018).
Jürgens, B., Hainz, U., Fuchs, D., Felzmann, T. & Heitger, A. Interferon-γ-triggered indoleamine 2,3-dioxygenase competence in human monocyte-derived dendritic cells induces regulatory activity in allogeneic T cells. Blood. https://doi.org/10.1182/blood-2008-12-195073 (2009).
Tsai, M. J. et al. Aryl hydrocarbon receptor agonists upregulate VEGF secretion from bronchial epithelial cells. J. Mol. Med.93, 1257–1269 (2015).
doi: 10.1007/s00109-015-1304-0
Budhu, S. et al. CD8+ T cell concentration determines their efficiency in killing cognate antigen–expressing syngeneic mammalian cells in vitro and in mouse tissues. J. Exp. Med. https://doi.org/10.1084/jem.20091279 (2010).
Hoves, S. et al. Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity. J. Exp. Med. https://doi.org/10.1084/jem.20171440 (2018).
Takenaka, M. C. et al. Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39. Nat. Neurosci. https://doi.org/10.1038/s41593-019-0370-y (2019).
Nguyen, N. T. et al. Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc. Natl Acad. Sci. USA. https://doi.org/10.1073/pnas.1014465107 (2010).
De Henau, O. et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. Nature539, 443–447 (2016).
Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. https://doi.org/10.1016/j.cell.2017.01.017 (2017).
Highfill, S. L. et al. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci. Transl. Med. https://doi.org/10.1126/scitranslmed.3007974 (2014).
Ngiow, S. F. et al. A threshold level of intratumor CD8+ T-cell PD1 expression dictates therapeutic response to anti-PD1. Cancer Res. https://doi.org/10.1158/0008-5472.CAN-15-1082 (2015).
Singh, N. P. et al. Activation of aryl hydrocarbon receptor (AhR) leads to reciprocal epigenetic regulation of Foxp3 and IL-17 expression and amelioration of experimental colitis. PLoS ONE. https://doi.org/10.1371/journal.pone.0023522 (2011).
Mezrich, J. D. et al. An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells. J. Immunol. https://doi.org/10.4049/jimmunol.0903670 (2010).
Liu, C. et al. Treg cells promote the SREBP1-dependent metabolic fitness of tumor-promoting macrophages via repression of CD8+ T cell-derived interferon-γ. immunity. https://doi.org/10.1016/j.immuni.2019.06.017 (2019).
Proto, J. D. et al. Regulatory T cells promote macrophage efferocytosis during inflammation resolution. Immunity49, 666–677.e6 (2018).
doi: 10.1016/j.immuni.2018.07.015
Bianchi-Smiraglia, A. et al. Inhibition of the aryl hydrocarbon receptor/polyamine biosynthesis axis suppresses multiple myeloma. J. Clin. Invest.128, 4682–4696 (2018).
doi: 10.1172/JCI70712
Yamada, T. et al. Constitutive aryl hydrocarbon receptor signaling constrains type I interferon-mediated antiviral innate defense. Nat. Immunol. https://doi.org/10.1038/ni.3422 (2016).
Huang, A. C. et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. https://doi.org/10.1038/nature22079 (2017).
Pilotte, L. et al. Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc. Natl Acad. Sci. USA. https://doi.org/10.1073/pnas.1113873109 (2012).
Li, H. et al. The landscape of cancer cell line metabolism. Nat. Med. https://doi.org/10.1038/s41591-019-0404-8 (2019).
Munn, D. H. et al. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med. https://doi.org/10.1084/jem.189.9.1363 (1999).
Hwu, P. et al. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J. Immunol. https://doi.org/10.4049/jimmunol.164.7.3596 (2000).
Li, H. et al. Metabolomic adaptations and correlates of survival to immune checkpoint blockade. Nat. Commun. https://doi.org/10.1038/s41467-019-12361-9 (2019).
Simpson, T. R. et al. Fc-dependent depletion of tumor-infiltrating regulatory t cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med.210, 1695–1710 (2013).
doi: 10.1084/jem.20130579
Fares, C. M., Van Allen, E. M., Drake, C. G., Allison, J. P. & Hu-Lieskovan, S. Mechanisms of resistance to immune checkpoint blockade: why does checkpoint inhibitor immunotherapy not work for all patients? Am. Soc. Clin. Oncol. Educ. B. 147–164. https://doi.org/10.1200/edbk_240837 (2019).
Hugo, W. et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell165, 35–44 (2016).
doi: 10.1016/j.cell.2016.02.065
Wheeler, M. A., Rothhammer, V. & Quintana, F. J. Control of immune-mediated pathology via the aryl hydrocarbon receptor. J. Biol. Chem. https://doi.org/10.1074/jbc.R116.767723 (2017).
Gutiérrez-Vázquez, C. & Quintana, F. J. Regulation of the immune response by the aryl hydrocarbon receptor. Immunity. https://doi.org/10.1016/j.immuni.2017.12.012 (2018).
Wang, G. Z. et al. The aryl hydrocarbon receptor mediates tobacco-induced PD-L1 expression and is associated with response to immunotherapy. Nat. Commun. https://doi.org/10.1038/s41467-019-08887-7 (2019).
Muranski, P. et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood112, 362–373 (2008).
doi: 10.1182/blood-2007-11-120998
Overwijk, W. W. et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med.198, 569–580 (2003).
doi: 10.1084/jem.20030590
Li, X., Kostareli, E., Suffner, J., Garbi, N. & Hämmerling, G. J. Efficient Treg depletion induces T-cell infiltration and rejection of large tumors. Eur. J. Immunol.40, 3325–3335 (2010).
doi: 10.1002/eji.201041093
Rooijen, N. Van & Sanders, A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J. Immunol. Methods174, 83–93 (1994).
doi: 10.1016/0022-1759(94)90012-4
P. Matheu, M., Sen, D., Cahalan, M. D. & Parker, I. Generation of bone marrow derived murine dendritic cells for use in 2-photon imaging. J. Vis. Exp. https://doi.org/10.3791/773 (2008).
Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013).
Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov.2, 401–404 (2012).
doi: 10.1158/2159-8290.CD-12-0095
Creighton, C. J. et al. Comprehensivemolecular characterization of clear cell renal cell carcinoma. Nature499, 43–49 (2013).
doi: 10.1038/nature12222
Cancer, T. et al. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature507, 315–322 (2014).
doi: 10.1038/nature12965

Auteurs

Luis Felipe Campesato (LF)

Swim Across America and Ludwig Collaborative Laboratory, Immunology Program, Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Immuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Sadna Budhu (S)

Swim Across America and Ludwig Collaborative Laboratory, Immunology Program, Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Immuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
ORCID: 0000-0002-3284-1408

Jeremy Tchaicha (J)

Ikena Oncology, Boston, MA, USA.

Chien-Huan Weng (CH)

Swim Across America and Ludwig Collaborative Laboratory, Immunology Program, Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Immuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
ORCID: 0000-0002-5478-9188

Mathieu Gigoux (M)

Swim Across America and Ludwig Collaborative Laboratory, Immunology Program, Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Immuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
ORCID: 0000-0002-1831-7597

Ivan Jose Cohen (IJ)

Department of Neurology and Louis V. Gerstner Jr Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.

David Redmond (D)

Swim Across America and Ludwig Collaborative Laboratory, Immunology Program, Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Immuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Levi Mangarin (L)

Swim Across America and Ludwig Collaborative Laboratory, Immunology Program, Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Immuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Stephane Pourpe (S)

Swim Across America and Ludwig Collaborative Laboratory, Immunology Program, Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Immuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Cailian Liu (C)

Swim Across America and Ludwig Collaborative Laboratory, Immunology Program, Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Immuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Roberta Zappasodi (R)

Swim Across America and Ludwig Collaborative Laboratory, Immunology Program, Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Immuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
ORCID: 0000-0002-7031-6671

Dmitriy Zamarin (D)

Swim Across America and Ludwig Collaborative Laboratory, Immunology Program, Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Immuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Jill Cavanaugh (J)

Ikena Oncology, Boston, MA, USA.

Alfredo C Castro (AC)

Ikena Oncology, Boston, MA, USA.

Mark G Manfredi (MG)

Ikena Oncology, Boston, MA, USA.

Karen McGovern (K)

Ikena Oncology, Boston, MA, USA.

Taha Merghoub (T)

Swim Across America and Ludwig Collaborative Laboratory, Immunology Program, Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA. merghout@mskcc.org.
Immuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. merghout@mskcc.org.
ORCID: 0000-0002-1518-5111

Jedd D Wolchok (JD)

Swim Across America and Ludwig Collaborative Laboratory, Immunology Program, Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA. wolchokj@mskcc.org.
Immuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. wolchokj@mskcc.org.
ORCID: 0000-0001-6718-2222

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Blockade of the AHR restricts a...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Résistance aux médicaments antinéoplasiques › Blockade of the AHR restricts a...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Blockade of the AHR restricts a...
questionsmedicales.fr › Phénomènes du système immunitaire › Immunomodulation › Tolérance immunitaire › Blockade of the AHR restricts a...
questionsmedicales.fr › Thérapeutique › Biothérapie › Immunothérapie › Blockade of the AHR restricts a...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Oxidoreductases › Oxygénases › Dioxygenases › Indoleamine-pyrrole 2,3,-dioxygenase › Blockade of the AHR restricts a...
questionsmedicales.fr › Acides aminés, peptides et protéines › Acides aminés › Cynurénine › Blockade of the AHR restricts a...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Phagocytes › Macrophages › Blockade of the AHR restricts a...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Blockade of the AHR restricts a...
questionsmedicales.fr › Tumeurs › Blockade of the AHR restricts a...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Antigènes de différenciation › Antigènes de différenciation des lymphocytes T › Récepteur-1 de mort cellulaire programmée › Blockade of the AHR restricts a...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Récepteurs à hydrocarbure aromatique › Blockade of the AHR restricts a...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Transduction du signal › Blockade of the AHR restricts a...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Sous-populations de lymphocytes T › Lymphocytes T régulateurs › Blockade of the AHR restricts a...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Oxidoreductases › Oxygénases › Dioxygenases › Tryptophane 2,3-dioxygenase › Blockade of the AHR restricts a...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Blockade of the AHR restricts a...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Microenvironnement cellulaire › Microenvironnement tumoral › Blockade of the AHR restricts a...